Evidence map›Paper›PMID 28746342›Full record

ArticlePloS one2017

The mechanism of monomer transfer between two structurally distinct PrP oligomers.

Aurora Armiento, Philippe Moireau, Davy Martin, Nad'a Lepejova, Marie Doumic, Human Rezaei

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aurora ArmientoUniv Paris Diderot, Sorbonne Paris Cité, Lab. J.L. Lions UMR CNRS 7598, Inria, Paris, France.
Philippe MoireauInria and Université Paris-Saclay, Campus de l'Ecole Polytechnique, 91128 Palaiseau, France.
Davy MartinINRA, UR892, Virologie Immunologie Moléculaires, 78350 Jouy-en-Josas, France.
Nad'a LepejovaINRA, UR892, Virologie Immunologie Moléculaires, 78350 Jouy-en-Josas, France.
Marie DoumicSorbonne Universités, Inria, UPMC Univ Paris 06, Lab. J.L. Lions UMR CNRS 7598, Paris, France.ORCID http://orcid.org/0000-0002-3183-8215
Human RezaeiINRA, UR892, Virologie Immunologie Moléculaires, 78350 Jouy-en-Josas, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In mammals, Prion pathology refers to a class of infectious neuropathologies whose mechanism is based on the self-perpetuation of structural information stored in the pathological conformer. The characterisation of the PrP folding landscape has revealed the existence of a plethora of pathways conducing to the formation of structurally different assemblies with different biological properties. However, the biochemical interconnection between these diverse assemblies remains unclear. The PrP oligomerisation process leads to the formation of neurotoxic and soluble assemblies called O1 oligomers with a high size heterodispersity. By combining the measurements in time of size distribution and average size with kinetic models and data assimilation, we revealed the existence of at least two structurally distinct sets of assemblies, termed Oa and Ob, forming O1 assemblies. We propose a kinetic model representing the main processes in prion aggregation pathway: polymerisation, depolymerisation, and disintegration. The two groups interact by exchanging monomers through a disintegration process that increases the size of Oa. Our observations suggest that PrP oligomers constitute a highly dynamic population.

Indexed as

Protein AggregatesProtein Aggregation, PathologicalProtein MultimerizationAlgorithmsAnimalsComputer SimulationKineticsModels, ChemicalPrionsProtein UnfoldingSheepPrionsProtein Aggregates

Identifiers

PMID28746342
PMCPMC5528842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.